Drug intelligence / Profile preview

PrrsvExoVac

Development stage: Preclinical
Lead developer: Innovex Therapeutics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics

Overview

**PrrsvExoVac** is an investigational veterinary extracellular-vesicle vaccine being developed by Innovex Therapeutics for prevention of porcine reproductive and respiratory syndrome. The candidate uses serum-derived exosomes collected from PRRSV-convalescent animals and is formulated with Montanide adjuvant. It is intended to present PRRSV-associated antigens to the porcine immune system, with reported induction of PRRSV-specific antibodies and CD8-positive T-cell responses in targeted pig studies. The program is preclinical.

Other names: PRRSV ExoVac

Beyond the preview

Go deeper on PrrsvExoVac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PrrsvExoVac.

Explore the full profile